Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Shire in a spin over Vyvanse.
- Shires shares have plummeted after high-profile brokers downgrade them on concerns customers aren't switching to its new ADHD drug, Vyvanse Richard Hemming First it was US-based broker Sanford C. Bernstein, then it was Goldman Sachs. Shire's share price has fallen off a...
- Research articles 2008-02-06
- Shire Successfully Completes Tender Offer for New River Shares.
- BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, April 18 /PRNewswire/ -- Shire plc (LSE: SHP.L; NASDAQ: SHPGY; TSX: SHQ) ("Shire" or the "Company") announced today that its wholly owned subsidiary, Shuttle Corporation ("Shuttle"), successfully completed its tender offer for the outstanding shares of ...
- Research articles 2007-04-18
- Results of Extraordinary General Meeting Held on 16 April 2007.
- BASINGSTOKE, England, April 16 /PRNewswire/ -- Shire plc (LSE: SHP.L; NASDAQ: SHPGY; TSX: SHQ) ("Shire" or the "Company") announced today that its shareholders approved the proposed acquisition of New River Pharmaceuticals Inc. (NASDAQ: NRPH) ("New River") at the Shire Extraordinary General Meeting...
- Research articles 2007-04-16
- Shire's Elaprase gets Greek distributor
- DISTRIBUTIONShire UK has chosen Samaritan Pharmaceutical US to market Elaprase, its treatment for Hunter syndrome, in Greece and Cyprus.Elaprase idursulfase was granted marketing authorization for the longterm treatment of patients with Hunter syndrome by the European Commission in January, having been given the green light in the US in July...
- Research articles 2007-04-01
- Shire Announces Posting of Circular, Date of Extraordinary General Meeting and Extension of Tender Offer for New River Shares Until April 17, 2007.
- BASINGSTOKE, England, March 26 /PRNewswire/ -- Shire plc (LSE: SHP.L; NASDAQ: SHPGY; TSX: SHQ) ("Shire" or the "Company") today announced the date of an Extraordinary General Meeting ("EGM") of its shareholders to approve the proposed acquisition of New River Pharmaceuticals Inc. (NASDAQ:...
- Research articles 2007-03-26
- SHIRE PLC - Merger Update.
- SHIRE ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD Basingstoke, UK - March 19, 2007 - Shire plc (LSE: SHP.L; NASDAQ: SHPGY; TSX: SHQ) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 HSR with respect to its wholly owned subsidiary's...
- Research articles 2007-03-19
- SHIRE PLC - Equity financing.
- SHIRE ANNOUNCES $800 MILLION EQUITY FINANCING IN CONNECTION WITH ACQUISITION OF NEW RIVER Basingstoke, UK and Philadelphia, US - February 20, 2007 - Shire plc (LSE: SHP, ...
- Research articles 2007-02-20
- Shire Announces US$800 Million Equity Financing in Connection With Acquisition of New River.
- BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, February 20 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ("Shire") announces today that, to part-finance its proposed acquisition by way of tender offer and merger of New River Pharmaceuticals Inc, it plans to raise...
- Research articles 2007-02-20
- Shire plc to Acquire New River Pharmaceuticals.
- M2 PRESSWIRE-20 February 2007-Early Watch: Shire plc to Acquire New River PharmaceuticalsC1994-2007 M2 COMMUNICATIONS LTD RDATE:20022007 New River Pharmaceuticals Inc. (NASDAQ:NRPH) is a specialty pharmaceutical company developing novel pharmaceuticals that are generational improvements of widely prescribed drugs in large and ...
- Research articles 2007-02-20
- New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD.
- BASINGSTOKE, England, PHILADELPHIA and RADFORD, Virginia, December 22 /PRNewswire/ -- - Launch Expected Q2 2007 New River Pharmaceuticals Inc. (Nasdaq: NRPH) and its collaborative partner Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug...
- Research articles 2006-12-22
- Issues Updates of Shire plc.
- M2 PRESSWIRE-20 October 2006-www.MarketGainer.com: Issues Updates of Shire plcC1994-2006 M2 COMMUNICATIONS LTD RDATE:20102006 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. Today's activity on the Nasdaq...
- Research articles 2006-10-20
- ADDERALL XR(R) - Paragraph IV Notice Received.
- BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, October 3 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) - Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that it has received a Paragraph IV notice letter from Andrx Pharmaceuticals, L.L.C. Andrx advising...
- Research articles 2006-10-03
- Shire's attention deficit disorder blow.
- The controversy over the safety of attention deficit hyperactivity disorder ADHD medicines, including Shire's Adderall XR, was renewed this week following the results of a study published in the New England Journal of Medicine. Using US government figures, the report estimates that 3,000 ...
- Research articles 2006-06-02
- Attention deficit boost for Shire.
- Shire unveiled positive data from Phase III trials of its new attention-deficit disorder drug NRP104 at a conference this week. And analysts at Morgan Stanley claim that the drug could be a blockbuster. But Japanese bank Nomura cut its recommendation on Shire from buy to reduce,...
- Research articles 2005-05-27
- The Week Ahead: GSK seeks relief from Puerto Rican ailment
- It is a big week for those following the pharmaceutical sector, with GlaxoSmithKline, AstraZeneca, SkyePharma and Shire Pharmaceuticals due to post results in the next five days. GSK's figures on Thursday will be the main focus as they are likely to be dominated by the manufacturing problems...
- Research articles 2005-04-25
- Property developer penalised for attempted price fix.
- M2 PRESSWIRE-27 January 2005-ACCC: Property developer penalised for attempted price fixC1994-2005 M2 COMMUNICATIONS LTD RDATE:01272005 Property developer Anglo Estates Pty Ltd attempted to enter into price-fixing and other anti-competitive arrangements with the Shire of Esperance over the sale of land in...
- Research articles 2005-01-27
- British Drug Firm Cools Investor Fears with Kidney Treatment News.
- Evening Standard, London Knight Ridder/Tribune Business News Nov. 4--Drugs group Shire Pharmaceutical issued positive news about its kidney disease treatment Fosrenol today as it tried to stem shareholder unease over the sacking of chief executive Rolf Stahel. American chairman James...
- Research articles 2002-11-04
- Shire obtains positive outcome in Biochem patent litigation.(Brief Article)
- Shire Pharmaceuticals Group plc (Andover, United Kingdom; 44 0 1264-348-515) announces a decision in favor of BioChem Pharma, Inc. (Laval, Canada; 450 978-7771) in the patent dispute between BioChem and Emory University (Atlanta, GA) relating to 3TC/Epivir lamivudine. On December 11, 2000, Shire and...
- Research articles 2000-12-01
- The Pfizer-Shire Deal Worst-Case Scenario
- Earlier this week shares of Shire rose on rumors that Pfizer may be interested in acquiring the company, which is best-known for its ADHD drug Adderall XR. The notion that Pfizer is in acquisition mode has been driving people crazy for days. (See BNET's coverage of Pfizer Pfever here.) ...
- Blog posts 2009-01-07
- Shire CEO Compensation Report Successfully Conceals CEO Compensation
- Shire, the British company that markets Adderall and Vyvanse, has produced a compensation report for its senior executives that is all but impossible to understand. The disclosure, starting on page 52 of the annual report, describes the compensation of just three of its top executives -- former...
- Blog posts 2009-03-25
- << Previous
- page 1 of 2
- Next >>
Content Types
Refining Tags
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
